


Status: Currently Official on 16-Feb-2025  
Official Date: Official as of 01-May-2020  
Document Type: USP Monographs  
DocId: GUID-3EAC65EF-3B27-4B1D-8F86-25A33D477A98\_2\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M1278\\_02\\_01](https://doi.org/10.31003/USPNF_M1278_02_01)  
DOI Ref: e35jt

© 2025 USPC  
Do not distribute

## Ractopamine Hydrochloride Suspension



$C_{18}H_{23}NO_3 \cdot HCl$  337.84

Benzinemethanol, 4-hydroxy- $\alpha$ -[[[3-(4-hydroxyphenyl)-1-methylpropyl]amino]methyl]-, hydrochloride;

( $\pm$ )-all-rac-*p*-Hydroxy- $\alpha$ -[[[3-(*p*-hydroxyphenyl)-1-methylpropyl]amino]methyl]benzyl alcohol, hydrochloride CAS RN®: 90274-24-1; UNII: 309G9J93TP.

### DEFINITION

Ractopamine Hydrochloride Suspension contains NLT 10% and NMT 20%, by weight, of ractopamine hydrochloride ( $C_{18}H_{23}NO_3 \cdot HCl$ ) in water.

[NOTE—The material partially precipitates out at room temperature to form a slurry, and redissolves when heated to 50°–60°.]

### IDENTIFICATION

*Change to read:*

- ▲ [SPECTROSCOPIC IDENTIFICATION TESTS \(197\), Infrared Spectroscopy: 197K](#) ▲ (CN 1-MAY-2020)

**Sample:** Dry a portion of Ractopamine Hydrochloride Suspension under vacuum for 3 h at 60°.

### ASSAY

#### • Procedure

**Solution A:** 5.75 mg/mL solution of monobasic ammonium phosphate adjusted with 10% phosphoric acid to a pH of  $4.0 \pm 0.1$

**Solution B:** 1.1 mg/mL solution of 1-heptanesulfonic acid sodium salt in *Solution A*

**Mobile phase:** Stabilizer-free tetrahydrofuran and *Solution B* (3:17)

**Diluent:** Stabilizer-free tetrahydrofuran and water (3:17). [NOTE—The *Standard solutions* and *System suitability solution* are stable for up to 72 h at room temperature. The *Sample solution* is stable for up to 90 h at room temperature.]

**System suitability solution:** 100  $\mu$ g/mL of [USP Ractopamine Hydrochloride RS](#) and 10  $\mu$ g/mL of [USP Raspberry Alcohol RS](#) in *Diluent*

**Standard solution A:** 0.08 mg/mL of [USP Ractopamine Hydrochloride RS](#) in *Diluent*

**Standard solution B:** 0.1 mg/mL of [USP Ractopamine Hydrochloride RS](#) in *Diluent*

**Standard solution C:** 0.12 mg/mL of [USP Ractopamine Hydrochloride RS](#) in *Diluent*

**Sample stock solution:** Stir Ractopamine Hydrochloride Suspension in a 60° water bath for up to 1 h, to ensure complete dissolution. While hot, transfer 700 mg of the Ractopamine Hydrochloride Suspension dropwise to a 100-mL volumetric flask, and dilute with *Diluent* to volume.

**Sample solution:** Dilute a portion of the *Sample stock solution* with *Diluent* (1:10).

#### Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 226 nm

**Column:** 4.6-mm  $\times$  15-cm; 5- $\mu$ m packing L1

**Flow rate:** 1 mL/min

**Injection size:** 20  $\mu$ L

#### System suitability

**Samples:** *System suitability solution* and *Standard solution B*

#### Suitability requirements

**Resolution:** NLT 1.5 between raspberry alcohol and ractopamine, *System suitability solution*

**Tailing factor:** NLT 0.7 and NMT 2.0 for the ractopamine peak, *Standard solution B*

**Relative standard deviation:** NMT 2.0% for three replicate injections, *Standard solution B*

### Analysis

**Samples:** *Standard solutions* and *Sample solution*

Prepare a calibration curve using the three ractopamine peak responses from *Standard solutions A, B, and C* and their corresponding concentrations. From the graph determine the concentration, C, in mg/mL, of ractopamine hydrochloride in the *Sample solution*.

Calculate the percentage (w/w) of  $C_{18}H_{23}NO_3 \cdot HCl$  in the portion of Ractopamine Hydrochloride Suspension taken:

$$\text{Result} = (V/W) \times C_s \times D \times 100$$

V = volume of the *Sample stock solution*, 100 mL

W = weight of Ractopamine Hydrochloride Suspension taken (mg)

$C_s$  = concentration of ractopamine hydrochloride from the *Sample solution*

D = dilution factor to prepare the *Sample solution*, 10

**Acceptance criteria:** 10%–20% of  $C_{18}H_{23}NO_3 \cdot HCl$

### IMPURITIES

#### ORGANIC IMPURITIES

##### • PROCEDURE

**Solution A:** 5.75 mg/mL of monobasic ammonium phosphate in water; pH NLT 4.4

**Solution B:** 1.1 mg/mL of 1-heptanesulfonic acid sodium salt in *Solution A*

**Solution C:** Acetonitrile and *Solution B* (1:9)

**Solution D:** Acetonitrile and *Solution B* (17:33)

**Mobile phase:** See the gradient table below.

Time (min)	Solution C (%)	Solution D (%)
0	100	0
22	0	100
32	0	100
37	100	0
55	100	0

**Diluent:** Acetonitrile and water (1:4)

**System suitability solution:** 9  $\mu$ g/mL each of [USP Raspberry Ketone RS](#) and [USP Ractopamine Hydrochloride RS](#) in *Diluent*

**Blank:** *Diluent*

**Sample solution A:** Stir Ractopamine Hydrochloride Suspension in a 60° water bath for up to 1 h, to ensure complete dissolution. While hot, transfer 200 mg of the Ractopamine Hydrochloride Suspension dropwise into a 50-mL volumetric flask, and dilute with *Diluent* to volume.

**Sample solution B:** Dilute a portion of *Sample solution A* with *Diluent* (1:100). [NOTE—The *Sample solutions* are stable for up to 48 h if stored at 5°.]

#### Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 226 nm

**Column:** 4.6-mm  $\times$  25-cm; 5- $\mu$ m packing L1

**Flow rate:** 1 mL/min

**Injection size:** 20  $\mu$ L

#### System suitability

**Sample:** *System suitability solution*

#### Suitability requirements

**Resolution:** NLT 2.0 between raspberry ketone and ractopamine

### Analysis

**Samples:** Blank, Sample solution A, and Sample solution B

[**NOTE**—Disregard any peaks that correspond to those in the *Blank*. Correct the response of the ractopamine peak in *Sample solution B* by subtracting the peak response at the retention time of ractopamine in the *Blank*.]

Calculate the percentage of each individual impurity in the portion of Ractopamine Hydrochloride Suspension taken:

$$\text{Result} = (r_A/r_B) \times 100/D$$

$r_A$  = peak response of each individual impurity from *Sample solution A*

$r_B$  = corrected peak response for ractopamine from *Sample solution B*

D = dilution factor to prepare *Sample solution B*, 100

### Acceptance criteria

**Individual impurities:** See [Impurity Table 1](#).

**Total impurities:** NMT 3.5%

**Impurity Table 1**

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Octopamine <sup>a</sup>	0.37	0.5
Tyramine <sup>b</sup>	0.55	0.5
N-Isopropyl octopamine <sup>c</sup>	0.63	0.5
Piperazinediphenol <sup>d</sup>	0.74	0.5
Aminobutylphenol <sup>e</sup>	0.76	0.5
Raspberry alcohol <sup>f</sup>	0.85	0.5
Raspberry ketone <sup>g</sup>	0.96	1.0
Ractopamine	1.0	—
Deoxyractopamine <sup>h</sup>	1.1	0.5
Ractopamine O-methyl <sup>i</sup>	1.2	1.0
Ractopamine N-hydroxy benzyl <sup>j</sup>	1.26	1.0
Ractopamine cyclohexyl analog <sup>k</sup>	1.29	0.5
Ractopamine dimer <sup>l</sup>	1.4	1.0
Any individual unspecified impurity	—	0.2

<sup>a</sup> 4-(2-Amino-1-hydroxyethyl)phenol.

<sup>b</sup> 4-(2-Aminoethyl)phenol.

<sup>c</sup> 4-[1-Hydroxy-2-(isopropylamino)ethyl]phenol.

- <sup>d</sup> 4,4'-(Piperazine-2, 5-diy) diphenol.
- <sup>e</sup> 4-(3-Aminobutyl)phenol.
- <sup>f</sup> 4-(3-Hydroxybutyl)phenol.
- <sup>g</sup> 4-(4-Hydroxyphenyl)butan-2-one.
- <sup>h</sup> 4-[3-(4-Hydroxyphenethylamino)butyl]phenol.
- <sup>i</sup> 4-{3-[2-(4-Hydroxyphenyl)-2-methoxyethylamino]butyl}phenol.
- <sup>j</sup> 4-(1-Hydroxy-2-[(4-hydroxybenzyl)[4-(4-hydroxyphenyl)butan-2-yl]amino]ethyl)phenol.
- <sup>k</sup> 4-(1-Hydroxy-2-[3-(4-hydroxyphenyl)-5-methylcyclohexylamino]ethyl)phenol.
- <sup>l</sup> 4,4'-(1,1'-Oxybis{2-[4-(4-hydroxyphenyl)butan-2-ylamino]ethane-1,1-diy})diphenol.

**SPECIFIC TESTS****• DIASTEROMER RATIO**

**Solution A:** 5.75 mg/mL of monobasic ammonium phosphate in water

**Solution B:** Add 10 mL of triethylamine to 950 mL of *Solution A*, dilute with *Solution A* to 1000 mL, and adjust with phosphoric acid to a pH of 4.5.

**Mobile phase:** Acetonitrile and *Solution B* (3:22)

**Diluent:** Acetonitrile and *Solution A* (1:4)

**System suitability solution:** 0.4 mg/mL of [USP Ractopamine Hydrochloride RS](#) in *Diluent*

**Sample solution:** Stir Ractopamine Hydrochloride Suspension in a 60° water bath for up to 1 h to ensure complete dissolution. While hot, transfer 275 mg of it dropwise into a 100-mL volumetric flask, and dilute with *Diluent* to volume.

[**NOTE**—The *Sample solution* is stable for up to 36 h when stored at ambient conditions.]

**Chromatographic system**

(See [Chromatography \(621\), System Suitability](#))

**Mode:** LC

**Detector:** UV 226 nm

**Column:** 4.6-mm × 25-cm; 5-μm packing L1

**Flow rate:** 1 mL/min

**Injection size:** 20 μL

**System suitability**

**Sample:** *System suitability solution*

[**NOTE**—The elution order is *RS,SR* diastereoisomer followed by *RR,SS* diastereoisomer.]

**Suitability requirements**

**Resolution:** NLT 1.25 between the diastereomers

**Analysis**

**Sample:** *Sample solution*

Calculate the *RS,SR* diastereomer content, in percentage:

$$\text{Result} = r_A / (r_A + r_B) \times 100$$

$r_A$  = peak response of the *RS,SR* diastereoisomer from the *Sample solution*

$r_B$  = peak response of the *RR,SS* diastereoisomer from the *Sample solution*

**Acceptance criteria:** 45%–49%

**ADDITIONAL REQUIREMENTS**

• **PACKAGING AND STORAGE:** Store at a temperature not exceeding 70°.

• **LABELING:** Label it to indicate that it is for veterinary use only.

• [USP Reference Standards \(11\)](#).

[USP Ractopamine Hydrochloride RS](#)

[USP Raspberry Alcohol RS](#)

4-(3-Hydroxybutyl)phenol.

$C_{10}H_{14}O_2$  166.22

[USP Raspberry Ketone RS](#)

4-(4-Hydroxyphenyl)butan-2-one.

$C_{10}H_{12}O_2$  164.20

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
RACTOPAMINE HYDROCHLORIDE SUSPENSION	<a href="#">Documentary Standards Support</a>	SM32020 Small Molecules 3
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	SM32020 Small Molecules 3

**Chromatographic Database Information:** [Chromatographic Database](#)

**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. PF 35(5)

**Current DocID: GUID-3EAC65EF-3B27-4B1D-8F86-25A33D477A98\_2\_en-US**

**DOI: [https://doi.org/10.31003/USPNF\\_M1278\\_02\\_01](https://doi.org/10.31003/USPNF_M1278_02_01)**

**DOI ref: [e35jt](#)**

OFFICIAL